Based upon the subgroup Assessment, we discovered that there was sizeable heterogeneity with regards to mortality, favorable results, and the total cure powerful price. Pertaining to mortality, The explanation for heterogeneity within the subgroup of edaravone dexborneol and EDV was primarily at